13 / 43
13
•
Vermorken JB, et al. N Engl J Med 2008;359:1116–27
•
CI, confidence interval; HR, hazard ratio
Overall survival
Cetuximab + platinum-based CT
CT alone
HR
OS
10.1 months
7.4 months
0.80 (95% CI: 0.64‒0.99), p=0.04
PFS
5.6 months
3.3 months
0.54 (95% CI: 0.43‒0.67), P<0.001
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
3
6
9
12
15
18
21
24
Months
Probability of overall survival
HR (95% CI): 0.80 (0.64–0.99); P=0.04
Cetuximab + CT (N=222)
200 173 127 83 65
47
19
8
1
222 184 153 118 82
57
30
15
3
No. at risk
CT alone
Cetuximab + CT
CT alone (N=220)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
3
6
9
12
15
Months
Probability of progression-free
survival
HR (95% CI): 0.54 (0.43–0.67), P<0.001
Cetuximab + CT (N=222)
CT alone (N=220)
No. at risk
CT alone
Cetuximab + CT
220
103
29
8
3
1
222
138
72
29
12
7
Progression-free survival
Median OS:
7.4 10.1
Median PFS:
3.3 5.6